Open Health has joined forces with health economics and outcomes research (HEOR) company Pharmerit International in a move that strengthens its existing market access capabilities.
Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.